


AMENDMENTS

In the Claims:

Claims 1-2. (Canceled).

3. (Currently amended) A compound of formula II,



wherein

Ar¹ is selected from the group consisting of phenyl, pyridinyl, quinolinyl, isoquinolinyl, thiophenyl, benzothiadiazolyl, isoxazolyl and oxazolyl,

Ar² is pyridinyl,

R⁶, R⁷ are independently H or A,

R⁸, R⁹ and R¹⁰ are independently selected from the group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH₂Hal, CH(Hal)₂, C(Hal)₃, NO₂, (CH₂)_nCN, (CH₂)_nNR¹¹R¹², (CH₂)_nO(CH₂)_kNR¹¹R¹², (CH₂)_nNR¹¹(CH₂)_kNR¹¹R¹², (CH₂)_nO(CH₂)_kOR¹¹, (CH₂)_nNR¹¹(CH₂)_kOR¹²,

$(\text{CH}_2)_n\text{COOR}^{13}$, $(\text{CH}_2)_n\text{COR}^{13}$, $(\text{CH}_2)_n\text{CONR}^{11}\text{R}^{12}$,
 $(\text{CH}_2)_n\text{NR}^{11}\text{COR}^{13}$, $(\text{CH}_2)_n\text{NR}^{11}\text{CONR}^{11}\text{R}^{12}$,
 $(\text{CH}_2)_n\text{NR}^{11}\text{SO}_2\text{A}$, $(\text{CH}_2)_n\text{SO}_2\text{NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{S(O)}_u\text{R}^{13}$,
 $(\text{CH}_2)_n\text{OC(O)R}^{13}$, $(\text{CH}_2)_n\text{COR}^{13}$, $(\text{CH}_2)_n\text{SR}^{11}$, CH=N-OA ,
 $\text{CH}_2\text{CH=N-OA}$, $(\text{CH}_2)_n\text{NHOA}$, $(\text{CH}_2)_n\text{CH=N-R}^{11}$,
 $(\text{CH}_2)_n\text{OC(O)NR}^{11}\text{R}^{12}$, $(\text{CH}_2)_n\text{NR}^{11}\text{COOR}^{13}$,
 $(\text{CH}_2)_n\text{N(R}^{11})\text{CH}_2\text{CH}_2\text{OR}^{13}$, $(\text{CH}_2)_n\text{N(R}^{11})\text{CH}_2\text{CH}_2\text{OCF}_3$,
 $(\text{CH}_2)_n\text{N(R}^{11})\text{C(R}^{13})\text{HCOOR}^{12}$,
 $(\text{CH}_2)_n\text{N(R}^{11})\text{C(R}^{13})\text{HCOOR}^{11}$,
 $(\text{CH}_2)_n\text{N(R}^{11})\text{CH}_2\text{CH}_2\text{N(R}^{12})\text{CH}_2\text{COOR}^{11}$,
 $(\text{CH}_2)_n\text{N(R}^{11})\text{CH}_2\text{CH}_2\text{NR}^{11}\text{R}^{12}$, CH=CHCOOR^{13} ,
 $\text{CH=CHCH}_2\text{NR}^{11}\text{R}^{12}$, $\text{CH=CHCH}_2\text{NR}^{11}\text{R}^{12}$,
 $\text{CH=CHCH}_2\text{OR}^{13}$, $(\text{CH}_2)_n\text{N(COOR}^{13})\text{COOR}^{14}$,
 $(\text{CH}_2)_n\text{N(CONH}_2)\text{COOR}^{13}$, $(\text{CH}_2)_n\text{N(CONH}_2)\text{CONH}_2$,
 $(\text{CH}_2)_n\text{N(CH}_2\text{COOR}^{13})\text{COOR}^{14}$,
 $(\text{CH}_2)_n\text{N(CH}_2\text{CONH}_2)\text{COOR}^{13}$,
 $(\text{CH}_2)_n\text{N(CH}_2\text{CONH}_2)\text{CONH}_2$, $(\text{CH}_2)_n\text{CHR}^{13}\text{COR}^{14}$,
 $(\text{CH}_2)_n\text{CHR}^{13}\text{COOR}^{14}$, $(\text{CH}_2)_n\text{CHR}^{13}\text{CH}_2\text{OR}^{14}$, $(\text{CH}_2)_n\text{OCN}$
and $(\text{CH}_2)_n\text{NCO}$, wherein

R^{11} , R^{12} are independently selected from the group consisting of H, A and (CH_2) ,

R^{13} , R^{14} are independently selected from the group consisting of H, Hal, A and $(\text{CH}_2)_m\text{Ar}^4$,

A is selected from the group consisting of alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy and alkoxyalkyl,

Ar^3 , Ar^4 are independently aromatic hydrocarbon residues comprising 5 to 12 carbon atoms which are optionally substituted by one or more substituents, selected from the group consisting of A, Hal, NO_2 , CN, OR^{15} , $\text{NR}^{15}\text{R}^{16}$, COOR^{15} , $\text{CONR}^{15}\text{R}^{16}$, $\text{NR}^{15}\text{COR}^{16}$, $\text{NR}^{15}\text{CONR}^{15}\text{R}^{16}$, $\text{NR}^{16}\text{SO}_2\text{A}$, COR^{15} , $\text{SO}_2\text{R}^{15}\text{R}^{16}$, $\text{S(O)}_u\text{A}$ and OOCR^{15} ,

R^{15} , R^{16} are independently selected from the group consisting of H, A, and $(\text{CH}_2)_m\text{Ar}^6$, wherein

Ar^6 is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH_2 and CF_3 ,

k, n and m are independently of one another 0, 1, 2, 3, 4, or 5;

X is O or ~~CH_2~~ ,

Y is O or S ~~selected from O and S~~,

p, r are independently 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4,




u is 0, 1, 2 or 3,






and






Hal is selected from the group consisting of F, Cl, Br and I;






and a pharmaceutically acceptable salt derivatives, ~~salts and solvates~~ thereof.


4. (Currently Amended) The compound according to claim 3, selected from the compounds of formula IIc, IId, IIg, IIh, IIi, IIj, ~~IIk, IIL, IIm, IIn, IIo, IIp, IIq, IIr, IIs, IIt, IIu, IIv, IIw and IIx,~~












IIw



IIx

wherein R^6 , R^7 , R^8 , p , Ar^1 , Y , X , R^9 , R^{10} and q are as defined in claim 3 and a pharmaceutically acceptable salt thereof ~~pharmaceutically acceptable salts and solvates thereof~~.

5. (Currently amended) The compound according to claim 4 3, selected from the compounds (1) to (2), (5) to (224) of table 1, the compounds (225) to (226), (229) to (448) (449) of table 2 and/or the compounds (449) (450) to (450) and (453) to (672) of table 3, and a pharmaceutically acceptable salt thereof ~~pharmaceutically acceptable salts and solvates thereof~~.

Claims 6-9. (Canceled).

10. (Currently Amended) A pharmaceutical composition, comprising the compound according to claim 3 in a pharmaceutical composition and further comprising an inert carrier.

Claims 11-29. (Canceled).

30. (Withdrawn/Previously presented) A method for producing compounds of formula II, wherein

a) a compound of formula III




wherein

FG is a functional group, selected from
 $-N=C=Y$ and $-NH-(C=Y)-LG$,
 wherein Y is as defined as in claim 3 and LG is a leaving group,

is reacted

b) with a compound of IV,



wherein

L^2 , L^3 are independently from one another H or a metal ion, and R^6 , R^7 ,
 E , G , M , Q , U , R^9 , q , X , Ar^2 , R^{10} and r are as defined in claim 3,

and optionally

- c) isolating and/or treating the compound of formula II obtained by said reaction with an acid, to obtain the salt thereof.

Claims 31-32. (Canceled).